A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)

October 22, 2019
https://clinicaltrials.gov/ct2/show/NCT039248561
Cancer - Bladder
Principal Investigator: Sheela Tejwani, MD

Muscle-invasive Bladder

Open